

SPECIFICATION AMENDMENTS

Please amend the paragraph at page 4, line 5, as follows:

FIG. 2 is a ~~FTIR spectrum for carvedilol Form VI~~ DSC thermogram for carvedilol Form VI.

Please amend the paragraph at page 4, line 6, as follows:

FIG. 3 is a ~~DSC thermogram for carvedilol Form VI~~ DTG thermogram for carvedilol Form VI.

Please amend the paragraph at page 4, lines 7, as follows:

FIG. 4 is a ~~DTG thermogram for carvedilol Form VI~~ FTIR spectrum for carvedilol Form VI.

Please amend the paragraph at page 4, lines 14-17, as follows:

Carvedilol solvate Form VI produces a FTIR spectrum (~~FIG. 2~~) (FIG. 4) with characteristic absorption bands at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1} . Further FTIR peaks were observed at about 720, 1100, 1286, 1454, 1589, 2911, and 2935 cm^{-1} .

Please amend the paragraph at page 4, lines 18-20, as follows:

Carvedilol solvate Form VI produces a DSC thermogram (~~FIG. 3~~) (FIG. 2) showing two endothermic peaks: the main endothermic peak was observed at about 74°C. and a minor endotherm ($\text{dH}=0.7\text{J/g}$) was observed at 112°C.


Please amend the paragraph at page 4, lines 21-24, as follows:

Carvedilol solvate Form VI produces a Differential Thermal Gravimetry (DTG) thermogram (~~FIG. 4~~) (FIG. 3) showing a weight loss step in the temperature range of 35-104°C. of about 13%. This value is equal to the expected value corresponding to two molecules of ethyl acetate per three molecules of carvedilol.

CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A crystalline solid of carvedilol ~~or a solvate thereof~~ characterized by data selected from the group consisting of a PXRD pattern with peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta, a DSC thermogram with endothermic peaks at about 74°C . and 112°C ., and a FTIR spectrum with peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1} .
2. (original) The carvedilol of claim 1 characterized by PXRD peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta.
3. (original) The carvedilol of claim 2 further characterized by PXRD peaks at about 5.8, 10.7, 11.1, 11.5, 13.1, 13.7, 16.8, 17.7, 18.5, and 23.0 ± 0.2 degrees two-theta.
4. (currently amended) The carvedilol of claim 3 characterized by a PXRD pattern substantially ~~a depicted in FIG. 1~~ as follows:




Serial No. 10/712,799

Attorney docket no. 1662/53605

5. (original) The carvedilol of claim 1 characterized by DSC peaks at about 74° C. and 112° C.


6. (currently amended) The carvedilol of claim 5 characterized by a DSC thermogram substantially as depicted in FIG. 3 follows:



7. (original) The carvedilol of claim 6 characterized by FTIR peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1} .

8. (original) The carvedilol of claim 7 further characterized by FTIR peaks at about 720, 1100, 1286, 1454, 1589, 2911, and 2935 cm^{-1} .

9. (currently amended) The carvedilol of claim 8 characterized by a FTIR spectrum as substantially depicted in FIG. 2 as follows:



10. (original) Crystalline carvedilol Form VI.

11-16. (canceled)

17. (currently amended) ~~The crystalline~~ A crystalline solid of carvedilol ~~or a solvate thereof~~ prepared by the a process of claim 11 comprising:
contacting carvedilol and ethyl acetate to form a solution and
cooling the solution whereby a precipitate is formed.

18. (currently amended) A pharmaceutical composition comprising an effective amount of the crystalline solid of carvedilol ~~or a solvate thereof~~ of claim 1 and at least one pharmaceutically acceptable excipient.

19. (original) A pharmaceutical dosage form comprising the pharmaceutical composition of claim 18.

20. (original) The pharmaceutical dosage form of claim 19 wherein the dosage form is an oral dosage form.

Serial No. 10/712,799
Attorney docket no. 1662/53605

21. (original) The pharmaceutical dosage form of claim 20 wherein the oral dosage form is a capsule or tablet.

22-27. (canceled)